Facing Pricing Pressure And Generic Erosion, Simcere Shifts To Innovative Products For Future Growth: China Earnings Roundup (Part I)
This article was originally published in PharmAsia News
China’s healthcare industry saw slower growth in the third quarter. In a recurring feature, PharmAsia News combs through earnings reports to bring you highlights of China’s leading pharma companies and how their efforts affect different sectors of the industry.
You may also be interested in...
BEIJING - Diabetes-focused Danish firm Novo Nordisk A/S is not deterred by a dip in China sales, and is planning to expand its R&D center and manufacturing capability in China to maintain its leading position in the country
NANJING, China - A few weeks after Merck & Co.'s China affiliate MSD and one of China's leading drug makers Simcere Pharmaceutical Group announced a new joint venture to expand access to critical lifestyle drugs across China, the two companies unveiled more details to their innovative partnership
SHANGHAI - China's State Council Aug. 4 released a formal draft of a new policy to address the abuse of anti-infectives and is soliciting public comments. Surprising analysts, the draft policy is less strict than a previous version that had circulated around industry, leaving the future of China's anti-infective market more difficult to predict